Can-Fite BioPharma (NYSE:CANF) Stock Rating Upgraded by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

Other research analysts also recently issued reports about the company. EF Hutton Acquisition Co. I upgraded Can-Fite BioPharma to a “strong-buy” rating in a research report on Wednesday, July 17th. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday.

Can-Fite BioPharma Stock Performance

CANF traded down $0.01 during trading on Tuesday, reaching $2.10. The company’s stock had a trading volume of 52,519 shares, compared to its average volume of 67,695. The company’s fifty day moving average price is $2.26 and its 200-day moving average price is $2.52. Can-Fite BioPharma has a 52-week low of $1.83 and a 52-week high of $4.69. The company has a market capitalization of $7.43 million, a price-to-earnings ratio of -1.17 and a beta of 1.39.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC boosted its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.